Analysts See $-1.19 EPS for Opiant Pharmaceuticals, Inc. (OPNT)

December 10, 2017 - By Darrin Black

 Analysts See $ 1.19 EPS for Opiant Pharmaceuticals, Inc. (OPNT)

Analysts expect Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) to report $-1.19 EPS on December, 15.They anticipate $0.89 EPS change or 296.67 % from last quarter’s $-0.3 EPS. After having $-0.17 EPS previously, Opiant Pharmaceuticals, Inc.’s analysts see 600.00 % EPS growth. The stock decreased 0.76% or $0.23 during the last trading session, reaching $30.01. About 24,529 shares traded. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) has 0.00% since December 10, 2016 and is . It has underperformed by 16.70% the S&P500.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company has market cap of $62.06 million. The firm offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It has a 43.75 P/E ratio. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine.

More notable recent Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) news were published by: which released: “Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization” on December 15, 2016, also with their article: “A Look At Opiant Pharmaceuticals, The Stock That Skyrocketed On Trump’s Opioid …” published on October 26, 2017, published: “Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions” on July 28, 2017. More interesting news about Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) were released by: and their article: “Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development …” published on July 19, 2017 as well as‘s news article titled: “Opiant bullish on opioid antagonist Narcan” with publication date: September 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: